Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Impairment expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Zomedica

Zomedica Corp. operates as a veterinary health company, which engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. It offers products for dogs and cats by focusing on the unmet needs of clinical veterinarians. Its TRUFORMA biosensor platform is designed to assist practitioners in the diagnosis of complex conditions. The company was founded by Gerald L. Solensky. on January 7, 2013 and is headquartered in Ann Arbor, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Zomedica reports revenue growth and product advancements amidst profitability challenges

Zomedica's 2022 performance reflects revenue growth and product advancements, though challenges in profitability persist. The company's strategic focus on companion animal healthcare presents growth opportunities through innovation and market stability. Addressing expense management, stock stability, and leveraging market trends will be key for Zomedica's future success.

Zomedica reports robust Q1 earnings, eyes global equine market

Zomedica's Q1 2023 showcased strong revenue growth, particularly driven by TRUFORMA and international sales.
The company's focus on maintaining margins, expanding marketing efforts, and targeting global equine markets positions it for future success.
Challenges include the closure of the cancer assay program and operational hurdles in achieving the 70% gross margin target.
Opportunities lie in the launch of new assays, international expansion, and investor engagement beyond quarterly updates.

Zomedica reports robust Q2 earnings, eyes international expansion and product launches

Zomedica's Q2 performance reflects strong revenue growth and strategic investments for future profitability.
Despite challenges like increased OpEx and lower margins, the company is focused on long-term growth through product launches and market expansion.
Opportunities lie in international market exploration, upcoming product launches, and investor engagement strategies.

Zomedica reports record revenues, eyes global expansion amidst stock challenges

Zomedica's Q3 performance reflects strong revenue growth and strategic acquisitions, despite facing challenges like potential delisting and net losses.
The company's focus on new product launches, international expansion, and partnerships presents opportunities for future growth and market diversification.
Overall, Zomedica aims to drive towards cash flow breakeven by leveraging innovative products and maintaining a strong liquidity position.

Zomedica reports record revenues, eyes profitability through strategic growth

Zomedica's strong financial performance in Q4 2023 and full-year results, coupled with a robust cash position and strategic growth initiatives, position the company for future success.
While facing challenges related to compliance requirements and integration costs, Zomedica's focus on innovation, market expansion, and profitability goals present opportunities for sustained growth.
By balancing operational efficiency, product development, and financial discipline, Zomedica aims to drive revenue growth, enhance market presence, and deliver long-term value to shareholders.

Zomedica reports revenue growth and strong cash position in Q1

Zomedica's Q1 2024 performance showed revenue growth driven by key segments, strong cash position, and focus on operational efficiency. The company faces challenges in managing expenses and achieving aggressive revenue targets. Opportunities lie in expanding product lines, international sales, and maintaining financial strength.

Zomedica reports Q2 revenue growth amidst challenges and opportunities

Zomedica's Q2 performance showed revenue growth but with challenges in sales force and noncash charges.
Strengths include achieving milestones and expanding facilities, while opportunities lie in international expansion.
The company faces the task of managing cash burn and finding a new CFO.
Expectations for the second half of 2024 include revenue growth and operational focus.

Zomedica reports record Q3 revenue, eyes global expansion opportunities

Zomedica's Q3 2024 performance showcased revenue growth, margin strength, and cost reduction efforts, positioning the company for future profitability. Strategic international partnerships and product innovations underscore growth potential.
While challenges in achieving profitability persist, Zomedica's focus on operational efficiency and global expansion presents opportunities for sustained growth. Addressing investor inquiries and executing on strategic initiatives will be key to unlocking future value.
With a solid cash position, ongoing product enhancements, and expansion into new markets, Zomedica is poised for growth. Clear communication on financial targets, operational milestones, and strategic direction will be crucial for investor confidence and market success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ANN ARBOR, MI / ACCESSWIRE / June 10, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced that Peter Donato, EVP and Chief Financial Officer, will present and host one-on-one meetings with investors at the Sidoti Small Cap Conference, taking place on June 12-13, 2024. The presentation will begin at 11:30 ET on June 12, 2024 and can be accessed live here: https://sidoti.zoom.us/webinar/register/WN_lHrKF7EPS3GHUfhDUtGFxg.

Zomedica to Present at the Sidoti Small Cap Conference June 12, 2024

New research data confirms superiority of TRUFORMA's Bulk Acoustic Wave Sensor technology in diagnosing feline hyperthyroidism ANN ARBOR, MI / ACCESSWIRE / June 6, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the presentation of research highlighting the improved diagnostic capabilities of the TRUFORMA® Bulk Acoustic Wave (BAW) platform when evaluating cats for thyroid disease compared to widely utilized chemiluminescent immunoassay (CLIA) platforms. The presentation, "Evaluation of a Feline-Optimized TSH Assay in Cats with Hyperthyroidism and with Non-Thyroidal Illness," will be given by Dr. Camille Brassard, DVM, IPSAV (Virginia-Maryland Regional College of Veterinary Medicine), at the American College of Veterinary Internal Medicine (ACVIM) Forum being held in Minneapolis, MN June 6 - 8, 2024.

Zomedica Announces Presentation of Compelling TRUFORMA(R) Research Findings and Educational Programs at Major Veterinary Internal Medicine Conference

Timely expansion enhances capacity amidst rapid sales growth ANN ARBOR, MI / ACCESSWIRE / June 4, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering diagnostic and therapeutic products for equine and companion animals, completed the expansion of its global manufacturing and distribution facilities in Roswell, Georgia. The expansion, which increases the facility's total size to 18,400 sq.

Zomedica Increases Manufacturing Capacity with Expansion of its Roswell, Georgia Facility; Can Support Production to Five times Current Levels

OTA capability enhances introduction of new assays from rapidly expanding menu ANN ARBOR, MI / ACCESSWIRE / May 15, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the launch of Over-the-Air ("OTA") software and firmware update capabilities for its TRUFORMA point-of-care diagnostic platform. "We recognized the need to deliver software and firmware updates remotely early in the TRUFORMA development," said Evan St. Peter, Vice President of Technology Innovation at Zomedica.

Zomedica Releases Over-the-Air Software Update Capabilities for Its TRUFORMA(R) Platform

Zomedica Corp. (NYSE:ZOM ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Larry Heaton - CEO Peter Donato - CFO Conference Call Participants Operator Good afternoon, ladies and gentlemen, and welcome to Zomedica First Quarter 2024 Financial Results Conference Call. At this time, all lines are in a listen-only mode.

Zomedica Corp. (ZOM) Q1 2024 Earnings Call Transcript

Performance Sets New Record for First Quarter Revenue ANN ARBOR, MI / ACCESSWIRE / May 9, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today reported consolidated financial results for the first quarter ended March 31, 2024. 2024 First Quarter Financial Highlights Revenue for the first quarter of 2024 grew 14% to $6.3 million, compared to first quarter 2023 revenue, driven by 9% growth over the prior year in the Therapeutic Devices segment and 86% growth over the prior year in the Diagnostics segment.

Zomedica Announces First Quarter 2024 Financial Results: Revenue up 14% to $6.3 Million; 66% Gross Margin, and $91 Million in Liquidity

ANN ARBOR, MI / ACCESSWIRE / May 8, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, will be participating in the EF Hutton Annual Global Conference, which will take place on May 15, 2024 at The Plaza Hotel in New York. Larry Heaton, Chief Executive Officer of Zomedica, will be presenting as well as holding one-on-one investor meetings throughout the day on May 15th.

Zomedica to Present at the EF Hutton Annual Global Conference on May 15, 2024

Key approval paves way for European expansion, tapping into a $4 billion vet services market ANN ARBOR, MI / ACCESSWIRE / May 6, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced that it has received CE certification for its VetGuardian® remote contactless monitoring system. The CE marking confirms that the VetGuardian system meets all EU health, safety, and environmental protection standards.

Zomedica Expands International Reach with CE Certification for VetGuardian(R) System

Intellectual property portfolio now includes 188 Patents and 131 Trademarks providing robust protection for the Company's product platforms ANN ARBOR, MI / ACCESSWIRE / May 2, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the issuance of three new patents, bolstering the intellectual property protection for its revolutionary TRUFORMA diagnostic platform. The TRUFORMA system provides veterinary professionals with reference laboratory accuracy directly at the point of care, enhancing the health management of horses and companion animals.

Zomedica Strengthens Market Position with New Patents Issued for its TRUFORMA(R) Diagnostic Platform

ANN ARBOR, MI / ACCESSWIRE / April 30, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, will host a conference call and audio-only webcast on Thursday, May 9th, 2024, at 4:30 p.m. ET to discuss the Company's operational and financial highlights for its first quarter ended March 31, 2024.

Zomedica to Report First Quarter 2024 Financial Results and Provide Business Update on May 9th at 4:30 p.m. ET

ANN ARBOR, MI / ACCESSWIRE / April 9, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic device products for equine and companion animals, today announced that its Chief Executive Officer, Larry Heaton, will present at the Noble Capital Markets' Emerging Growth Virtual Healthcare Equity Conference on Wednesday, April 17, 9:30 a.m. - 10:00 a.m.

Zomedica to Present at the Noble Capital Markets Virtual Healthcare Conference on April 17, 2024

Zomedica Corp. (ZOM) Q4 2023 Earnings Call Transcript

ANN ARBOR, MI / ACCESSWIRE / April 1, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic device products for equine and companion animals, today reported consolidated financial results for the fourth quarter and year-ended December 31, 2023. All figures are in US dollars unless otherwise stated.

Zomedica Reports Record Revenue of $7.3 Million for the Fourth Quarter and $25.2 Million for the Full Year 2023, Reflecting 33% Annual Growth; 69% Gross Margin and $100.5 Million in Liquidity

Blade Air Mobility

SNDL Inc.

In investing, the allure of penny stocks attracts seasoned investors and newcomers alike. Small-cap stocks often trade on mere cents, but they can potentially yield massive returns.

The Next Millionaire-Makers: 3 Penny Stocks With Massive Upside Potential

ANN ARBOR, MI / ACCESSWIRE / March 20, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, will host a conference call and audio-only webcast on Monday, April 1st, 2024, at 4:30 p.m. ET to discuss the Company's operational and financial highlights for its fourth quarter and full year ended December 31, 2023.

Zomedica to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Monday, April 1, 2024, at 4:30 p.m. ET

ANN ARBOR, MI / ACCESSWIRE / March 14, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the publication of a peer-reviewed research study favorably comparing the capabilities for the diagnosis of feline hyperthyroidism of its novel, point-of-care TRUFORMA Bulk Acoustic Wave (BAW) diagnostic platform to chemiluminescent immunoassay (CLIA) platforms currently broadly utilized by reference laboratories globally. The authors conclude that, "this new TSH-BAW assay more accurately identifies hyperthyroid cats than the current TSH-CLIA assay and would improve the early diagnosis of hyperthyroidism.

Zomedica Announces Publication of Research Concluding TRUFORMA(R) Platform is More Accurate Diagnostic Test for Feline Hyperthyroidism than Chemiluminescent Immunoassay (CLIA) Platform

ANN ARBOR, MI / ACCESSWIRE / March 13, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced that it is continuing dialogue with senior regulatory staff at the NYSE American regarding next steps to regaining compliance with its listing standards. Zomedica shares will remain listed on the NYSE American at this time.

Zomedica Provides NYSE American Listing Update

ANN ARBOR, MI / ACCESSWIRE / March 12, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today announced the presentation of veterinary education programs scheduled at the upcoming Fetch dvm360 Veterinary Conference and subsequent dvm360 Fetch programs. "The 'Fetch' series of veterinarian Continuing Education (CE) programs by dvm360 is the ideal format for presenting Zomedica's groundbreaking technologies to animal healthcare professionals, and our close relationship with this organization provides us with an exceptional opportunity to bring awareness to veterinarians about the many ways Zomedica's products and services can benefit them and their patients," commented Nicole Westfall, Zomedica's Senior Vice President of Marketing.

Zomedica Announces Sponsorship of Educational Presentations at Fetch dvm360 Veterinary Conferences

ANN ARBOR, MI / ACCESSWIRE / March 7, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the publication of a case series article supporting the use of PulseVet electro-hydraulic shock wave therapy to successfully treat canine patients with fibrotic myopathy. This condition primarily affects breeds associated with Military and Police working dogs, such as German Shepherd Dogs.

Zomedica Announces Publication of Case Series Highlighting Success with PulseVet(R) Shock Wave Therapy for Difficult to Treat Fibrotic Myopathy in Working Dogs

ANN ARBOR, MI / ACCESSWIRE / March 5, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced that Larry Heaton, Chief Executive Officer, will present and host one-on-one meetings with investors at the Sidoti Small Cap Conference, taking place virtually on March 14th, 2024. The Company's presentation will take place at 10:00 am ET on Thursday, March 14, 2024, and can be accessed directly on the official Sidoti Conference website.

Zomedica to Present at the Sidoti Small Cap Conference March 14, 2024

Castor Maritime Inc

Due to the fact that the stock market is in a constant state of flux, high-reward penny stocks often surface as hidden gems, luring purchasers with the promise of substantial rewards. Investing in such companies carries some risk but is a good way for smart investors to get rich.

3 High-Reward Penny Stocks to Uncover Big Gains

ANN ARBOR, MI / ACCESSWIRE / February 8, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today announced the continuation of its veterinary education mission through recent and upcoming presentations at the Veterinary Meeting and Expo ("VMX") and Western Veterinary Conference ("WVC") meetings. "At Zomedica, we feel strongly about giving back to the veterinary community.

Zomedica Announces Sponsorship of Educational Presentations at Major Veterinary Health Conferences

Bionano Genomics

Ideanomics Inc

Phunware Inc

Tellurian

Now might be a good time to consider scooping up shares of penny stocks to buy on the dip. However, caution is essential, as penny stocks can be volatile and speculative.

7 Penny Stocks to Buy on the Dip: February 2024

ANN ARBOR, MI / ACCESSWIRE / February 6, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today announced that Glass Lewis, a leading independent proxy voting and corporate governance advisory firm is recommending that shareholders vote "FOR" the proposed Share Consolidation/Reverse Stock Split as detailed in the Company's definitive proxy statement filed on January 17, 2024. Shareholders will be asked to vote on the Reverse Stock Split at Zomedica's upcoming special meeting of shareholders scheduled to be held on February 28, 2024.

Leading Independent Proxy Advisory Firm Glass Lewis Recommends Zomedica Shareholders Vote for the Share Consolidation (Reverse Stock Split)

ANN ARBOR, MI / ACCESSWIRE / February 6, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today announced that it will be hosting a Virtual Investor Day event on Tuesday, February 13, 2024, starting at 3:00 p.m. ET. The virtual-only webcast event will feature presentations from select members of the management team.

News for Zomedica Stock (ZOM)